TCL Archive NCI Alternative to Fixed Number Of Grants Not Popular At NIH; AACR Considers New Issues Groups July 15, 1983
TCL Archive ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial. September 8, 2006
TCL Archive Patient Groups Are Focus of New Alliances In a Shift of Cancer Advocacy Agenda May 31, 1996